Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Depreciation & Amortization (CF): 2015-2024

Historic Depreciation & Amortization (CF) for Intellia Therapeutics (NTLA) over the last 10 years, with Dec 2024 value amounting to $10.3 million.

  • Intellia Therapeutics' Depreciation & Amortization (CF) fell 7.69% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.0 million, marking a year-over-year decrease of 2.17%. This contributed to the annual value of $10.3 million for FY2024, which is 14.44% up from last year.
  • As of FY2024, Intellia Therapeutics' Depreciation & Amortization (CF) stood at $10.3 million, which was up 14.44% from $9.0 million recorded in FY2023.
  • Intellia Therapeutics' Depreciation & Amortization (CF)'s 5-year high stood at $10.3 million during FY2024, with a 5-year trough of $6.3 million in FY2020.
  • Over the past 3 years, Intellia Therapeutics' median Depreciation & Amortization (CF) value was $9.0 million (recorded in 2023), while the average stood at $9.0 million.
  • Data for Intellia Therapeutics' Depreciation & Amortization (CF) shows a peak YoY increased of 18.42% (in 2023) over the last 5 years.
  • Yearly analysis of 5 years shows Intellia Therapeutics' Depreciation & Amortization (CF) stood at $6.3 million in 2020, then rose by 9.33% to $6.9 million in 2021, then increased by 10.14% to $7.6 million in 2022, then climbed by 18.42% to $9.0 million in 2023, then climbed by 14.44% to $10.3 million in 2024.